Safety analysis of a Russian phage cocktail: From MetaGenomic analysis to oral application in healthy human subjects

Phage therapy has a long tradition in Eastern Europe, where preparations are comprised of complex phage cocktails whose compositions have not been described. We investigated the composition of a phage cocktail from the Russian pharmaceutical company Microgen targeting Escherichia coli/Proteus infect...

Full description

Saved in:
Bibliographic Details
Published inVirology (New York, N.Y.) Vol. 443; no. 2; pp. 187 - 196
Main Authors McCallin, Shawna, Alam Sarker, Shafiqul, Barretto, Caroline, Sultana, Shamima, Berger, Bernard, Huq, Sayeda, Krause, Lutz, Bibiloni, Rodrigo, Schmitt, Bertrand, Reuteler, Gloria, Brüssow, Harald
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.09.2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Phage therapy has a long tradition in Eastern Europe, where preparations are comprised of complex phage cocktails whose compositions have not been described. We investigated the composition of a phage cocktail from the Russian pharmaceutical company Microgen targeting Escherichia coli/Proteus infections. Electron microscopy identified six phage types, with numerically T7-like phages dominating over T4-like phages. A metagenomic approach using taxonomical classification, reference mapping and de novo assembly identified 18 distinct phage types, including 7 genera of Podoviridae, 2 established and 2 proposed genera of Myoviridae, and 2 genera of Siphoviridae. De novo assembly yielded 7 contigs greater than 30kb, including a 147-kb Myovirus genome and a 42-kb genome of a potentially new phage. Bioinformatic analysis did not reveal undesired genes and a small human volunteer trial did not associate adverse effects with oral phage exposure. •We analyzed the composition of a commercial Russian phage cocktail.•The cocktail consists of at least 10 different phage genera.•No undesired genes were detected.•No adverse effects were seen upon oral application in a small human clinical trial.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0042-6822
1096-0341
1096-0341
DOI:10.1016/j.virol.2013.05.022